

1 **Angiotensin-converting enzyme inhibition and Alzheimer's disease: Findings from**
2 **proteome-wide Mendelian randomization and a large prospective cohort study**

3 Peiyuan Huang^{1,2,3,4,†}, Haibo Tang^{5,6,†}, Zeying Feng^{7,†}, Evie Stergiakouli^{1,4}, Tom R Gaunt^{1,4,8},
4 Jie Zheng^{1,2,3*}, Yao Lu^{5,9*}

5 ¹Medical Research Council Integrative Epidemiology Unit, Bristol Medical School,
6 University of Bristol, Oakfield House, Oakfield Grove, Bristol, BS8 2BN, United Kingdom

7 ²Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and
8 Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197
9 Ruijin 2nd Road, Shanghai, 200025, China

10 ³Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory for
11 Endocrine and Metabolic Diseases of the National Health Commission of the People's
12 Republic of China, Shanghai Key Laboratory for Endocrine Tumor, State Key Laboratory of
13 Medical Genomics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197
14 Ruijin 2nd Road, Shanghai, 200025, China

15 ⁴Population Health Sciences, Bristol Medical School, University of Bristol, Oakfield House,
16 Oakfield Grove, Bristol, BS8 2BN, United Kingdom

17 ⁵Clinical Research Center, The Third Xiangya Hospital, Central South University, 138
18 Tongzipo Road, Changsha, Hunan, 410013, China

19 ⁶Department of Metabolic and Bariatric Surgery, The Third Xiangya Hospital, Central South
20 University, 138 Tongzipo Road, Changsha, Hunan, 410013, China

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

1 ⁷Clinical Trial Institution Office, Liuzhou Hospital of Guangzhou Women and Children's
2 Medical Center, 50 Boyuan Avenue, Liuzhou, Guangxi, 545006, China

3 ⁸National Institute for Health and Care Research Bristol Biomedical Research Centre,
4 Oakfield House, Oakfield Grove, Bristol, BS8 2BN, United Kingdom

5 ⁹School of Life Course Sciences, King's College London, Addison House, Guy's Campus,
6 London, SE1 1UL, United Kingdom

7 † Peiyuan Huang, Haibo Tang, and Zeying Feng have contributed equally to this work.

8 * Corresponding authors.

9 Professor Jie Zheng, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine,
10 197 Ruijin 2nd Road, Shanghai, 200025, China. E-mail address: jie.zheng@bristol.ac.uk

11 Professor Yao Lu, The Third Xiangya Hospital, Central South University, 138 Tongzipo
12 Road, Changsha, Hunan, 410013, China. E-mail address: luyao0719@163.com

1 **ABSTRACT**

2 **Background:** We aimed to provide clinically translatable insights for drug discovery,
3 repurposing, and vigilance for preventing Alzheimer’s disease (AD) by integrating genetic
4 and “real-world” drug use data.

5 **Methods:** Proteome-wide Mendelian randomization (MR) analysis was conducted to identify
6 plasma proteins causally related to AD risk using the largest summary-level data to date,
7 followed by colocalization and multi-omic validation analyses (on the gene expression,
8 alternative splicing, and DNA methylation levels in blood and brain, respectively) to
9 prioritize potential druggable targets. We also replicated our MR findings using additional
10 genetic data and, where appropriate, performed multivariable MR for the prioritized findings.
11 Conventional observational analysis using the data from UK Biobank, a large prospective
12 cohort, was performed to provide further clinical implications for our genetic findings.

13 **Results:** MR analysis identified 15 plasma proteins with putative causal effects on AD risk.
14 Of them, inhibition of angiotensin-converting enzyme (ACE) was found to increase the risk
15 of AD (OR 1.10, 95% CI 1.08-1.14), which was likely independent of blood pressure as
16 suggested by multivariable MR. Observational analysis in UK Biobank showed a higher
17 incidence (HR 1.24, 95% CI 1.01-1.52) of AD among regular users of ACE inhibitors (ACEI),
18 compared with the counterpart angiotensin receptor blocker users.

19 **Conclusions:** In addition to expanding the understanding of druggable targets for AD
20 prevention, our findings highlighted the potential risk of AD associated with the use of
21 ACEIs, a widely prescribed antihypertensive medication, suggesting the need for caution in
22 clinical practice and further research on the effect of antihypertensives on neurodegenerative
23 diseases.

1 **Key Words**

- 2 plasma protein; Alzheimer's disease; Mendelian randomization; angiotensin-converting
- 3 enzyme; angiotensin-converting enzyme inhibitor; hypertension

1 INTRODUCTION

2 Alzheimer's disease (AD) is one of the most prevalent neurodegenerative disorders,
3 characterized by irreversible neuronal death and progressive cognitive impairment. As the
4 leading cause of dementia, AD affects approximately 50 million individuals worldwide and
5 poses a significant medical and social burden¹. With an aging population, the global
6 incidence of dementia is expected to increase to 150 million by 2050². Despite extensive
7 research, the pathogenesis of AD remains elusive, and few effective preventive or therapeutic
8 strategies have been established^{3,4}. Therefore, there is an urgent need to develop novel
9 approaches to prevent and treat AD.

10 The human proteome provides a valuable resource for gaining insights into the pathogenesis
11 of AD and identifying potential biomarkers and druggable targets. Our previous study
12 demonstrated the translational value of drug target discovery for complex diseases using
13 proteome-wide Mendelian randomization (MR)⁵. Since then, several proteome-wide MR
14 studies of blood and/or brain have identified various proteins as potential drug targets for AD
15⁶⁻⁹. However, these findings were obtained and validated only using genetic tools and lacked
16 observational evidence from "real-world" drug use data, thus limiting their reliability.

17 Aiming to reveal the pathogenesis of AD and facilitate discovery, repurposing, and vigilance
18 of drugs for AD prevention, we first conducted a proteome-wide MR analysis, followed by
19 sensitivity and replication analyses as well as multi-omic validation. For any targets
20 identified by this process, we integrated observational evidence based on UK Biobank data
21 on drug use to further validate them and explore their clinical implications. An overview of
22 the study design is shown in **Figure 1**. By incorporating "real-world" drug use data into
23 omics-based approaches, we can link omics-based research findings with clinical practice,
24 fostering a deeper understanding of the underlying mechanisms of AD, facilitating the

1 development of more effective preventive measures, or identifying existing drugs that may
2 decrease or increase the risk of AD.

3 **METHODS**

4 **Mendelian randomization**

5 *Genetic associations with plasma proteins*

6 We used protein quantitative trait loci (pQTL) instrument data from our previous study by
7 Zheng et al. ⁵, which integrated five published pQTL studies and identified 1,064 tier 1 (i.e.,
8 with the highest relative level of reliability) pQTL instruments for 955 proteins.⁵ Tier 1 pQTL
9 instruments were further categorized into three groups: (1) *cis*-pQTLs (including single-*cis*-
10 pQTLs [with only one *cis*-pQTL available for each protein] and multiple-*cis*-pQTLs [with
11 more than one *cis*-pQTLs available for each protein]), (2) *cis* + *trans*-pQTLs, and (3) *trans*-
12 pQTLs. As *trans*-acting pQTLs may operate via indirect mechanisms and are therefore more
13 likely to be pleiotropic ¹⁰, we only focused on tier 1 single-*cis*-, multiple-*cis*-, and *cis* + *trans*-
14 pQTLs in this study.

15 *Genetic associations with Alzheimer's disease*

16 Outcome genome-wide association study (GWAS) data were from the latest and largest
17 published AD GWAS by Bellenguez et al. ¹¹, including 111,326 clinically diagnosed/“proxy”
18 AD cases and 677,663 controls of European ancestry, from the following consortia/datasets:
19 EADB, GR@ACE, EADI, GERAD/PERADES, DemGene, Bonn, the Rotterdam study, the
20 CCHS study, Nx-C, and the UK Biobank ¹². In the UK Biobank, individuals who did not
21 report dementia or any family history of dementia were used as controls, and the analysis

1 included 2,447 diagnosed cases, 46,828 proxy cases of dementia, and 338,440 controls ¹¹.

2 There was no sample overlap between the pQTL studies and the AD GWAS.

3 *Genetic associations with gene expression, gene expression, alternative splicing, and DNA*
4 *methylation*

5 Blood *cis*-expression quantitative trait loci (*cis*-eQTL) data were obtained from the eQTLGen
6 Consortium (<https://www.eqtlgen.org/>), which incorporates 37 datasets to identify the
7 downstream consequences of trait-related genetic variants, with a total of 31,684 individuals
8 ¹³. Brain *cis*-eQTL data were accessed from a recent eQTL mapping analysis by Qi et al ¹⁴.
9 using RNA sequencing data of brain cortex (N = 2,865) with genome-wide single nucleotide
10 polymorphism (SNP) data. Blood *cis*-splicing quantitative trait loci (*cis*-sQTL) data were
11 obtained from the Genotype-Tissue Expression (GTEx, <https://gtexportal.org/>) Analysis V8
12 (N = 670), assessing the association between genetic variants and intron excisions using the
13 LeafCutter approach ¹⁵. Brain cortex *cis*-sQTL data were also accessed from Qi et al.'s study
14 ¹⁴, which used an sQTL mapping method called testing for heterogeneity between isoform-
15 eQTL effects (THISTLE) and identified 12,794 genes with *cis*-sQTLs at $P < 5 \times 10^{-8}$. Blood
16 *cis*-methylation quantitative trait loci (*cis*-mQTL) data were extracted from the Genetics of
17 DNA Methylation Consortium (GoDMC, <http://mqtl.db.godmc.org.uk/>), which identified
18 genetic variants associated with DNA methylation (DNAm) at 420,509 cytosine-phosphate-
19 guanine (CpG) sites in blood among 27,750 individuals of European ancestry. Brain *cis*-
20 mQTL data were obtained from the meta-analysis by Qi et al. (N = 526 to 1194) ¹⁶.

21 *Genetic association data for replication*

22 In addition to the combination of exposure and outcome GWAS data in our MR main
23 analysis (i.e., Zheng et al. – Bellenguez et al.), replication analysis was performed using the

1 data from different pQTL studies and AD GWASes. For the exposure (protein abundance)
2 GWAS, we used the data from a recent pQTL study by Gudjonsson et al ¹⁷. This study
3 examined 4,035 independent associations between genetic variants and 2,091 serum proteins
4 in 5,368 individuals aged between 66 and 96 years from the AGES-Reykjavik Study ¹⁸.
5 pQTL full summary data were available for all of our top-hit proteins. For the outcome
6 (Alzheimer's disease), we used the data from three GWASes. The first one, by
7 Schwartzentruber et al. ¹⁹, included a total of 75,024 cases (including those with diagnosed
8 AD and who reported a family history of dementia) and 397,844 controls from a previous
9 GWAS ²⁰ and the UK Biobank ¹². The second one, by Kunkle et al. ²⁰, was a subset of
10 Schwartzentruber et al.'s GWAS samples, which included 21,982 cases with diagnosed AD
11 and 41,944 controls. The third one, by Wightman et al. ²¹, was a subset of a large GWAS
12 meta-analysis excluding 23andMe data, including 86,531 cases and 676,386 controls. We
13 selected these three GWASes because Schwartzentruber et al.'s and Wightman et al.'s studies
14 were two of the largest and latest AD GWASes following Bellenguez et al.'s study, and
15 Kunkle et al.'s study only recruited diagnosed AD cases, whose results were thus more
16 clinically relevant.

17 *Genetic associations with blood pressure*

18 In follow-up analyses, we conducted multivariable MR to adjust for blood pressure. To avoid
19 potential collider bias caused by adjustment for body size in the GWAS ²², genetic
20 association data for systolic (SBP) and diastolic blood pressure (DBP) were obtained from
21 the UK Biobank GWASes (SBP GWAS ID: ukb-b-20175; DBP GWAS ID: ukb-b-7992) of
22 ~436,420 males and females of European ancestry, accessed through the IEU OpenGWAS
23 Project (<http://gwas.mrcieu.ac.uk/>) ²³.

24 **Conventional observational study**

1 *Study population*

2 The UK Biobank is a prospective cohort study recruiting over 500,000 million middle-aged
3 participants at 22 assessment centers across the UK between 2006 and 2010. When recruited,
4 participants provided blood, urine, and saliva samples at the nearest assessment center with
5 their consent, as well as detailed information about sociodemographic, lifestyle, health-
6 related factors, environment, and medical history via touchscreen and face-to-face interviews.
7 Physical measurements were taken, including height, weight, and blood pressure. Follow-up
8 assessments were conducted using routinely available national datasets. To avoid potential
9 confounding by indications, we restricted our study to participants with either angiotensin-
10 converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) medication
11 records. Individuals were further excluded if they met any of the following criteria at baseline:
12 1) with a diagnosis of AD before baseline [International Classification of Diseases 10 (ICD-
13 10) codes: F00 and G30]; 2) with a family history of AD.

14 *Measurement of medication use*

15 According to the Anatomical Therapeutic Chemical (ATC) classification ²⁴, ACEIs and
16 ARBs were defined with the code C09AA and C09CA, respectively. Combining the
17 medication records at baseline in UK Biobank, participants who had been using the drugs
18 (ACEIs or ARBs) most days of the week for the last four weeks, were classified as regular
19 users of ACEIs or ARBs.

20 *Ascertainment of Alzheimer's disease*

21 AD cases were identified by the diagnosis records with ICD-10 code F00 and G30 ²⁵,
22 followed up to 30 September 2021. The date of diagnosis was set as the date of the first AD

1 diagnosis record. Person-time was taken from the date of baseline and censored at the date of
2 AD diagnosis, date of death, or 30 September 2021, whichever occurred earliest.

3 *Assessment of covariates*

4 At baseline, participants provided demographic and lifestyle behaviors information, including
5 age at recruitment, sex, ethnicity, smoking status, alcohol consumption frequency, income
6 score (UKB Data Field 26411, with higher scores indicating higher income levels), education
7 score (UKB Data Field 26414; with higher scores indicating higher education levels), and
8 comorbidities. Body mass index (BMI; in kg/m²) was calculated by weight (in kg) divided by
9 squared height (in m). The comorbidities were identified by ICD-10 at baseline, including
10 hypertension, diabetes, hyperlipidemia, traumatic brain injury, cerebrovascular diseases, and
11 nervous system diseases (ICD-10 codes: I60-I69). In addition, we also calculated the number
12 of long-term conditions as covariates. Detailed definitions of long-term conditions were
13 described elsewhere ²⁶.

14 **Statistical analyses**

15 *Proteome-wide Mendelian randomization*

16 For single-*cis*-pQTLs, we performed a standard two-sample MR analysis for each protein
17 with the Wald ratio method ^{27, 28}. For multiple-*cis*-pQTLs, MR estimates may be sensitive to
18 the particular choice of pQTLs if only the most strongly associated SNPs within each
19 genomic region are used as instruments ⁵. It has been suggested that more precise causal
20 estimates can be obtained using multiple genetic variants from a single gene region, even if
21 the variants are correlated ^{29, 30}. Therefore, we used multiple conditionally independent *cis*-
22 pQTLs for this MR analysis. Specifically, we conducted linkage disequilibrium (LD)
23 clumping with a relaxed threshold of $r^2 < 0.6$ to avoid highly LD-correlated SNPs; the

1 resulting single-*cis*-pQTLs (i.e., multiple-*cis*-pQTLs with highly LD-correlated SNPs
2 removed by clumping) were picked back to the single-*cis* analysis above; for the rest
3 multiple-*cis*-pQTLs, we used a generalized inverse variance-weighted (IVW)³¹ method for
4 each protein considering the LD pattern between the multiple-*cis* SNPs to estimate the MR
5 effects, where the pairwise LD correlation (r^2) were obtained from the 1000 Genomes
6 European ancestry reference samples. For *cis* + *trans*-pQTLs, a standard two-sample MR
7 analysis was performed for each protein, with $r^2 < 0.001$ as the threshold for LD-clumping
8 and standard IVW as the MR method^{28,32}. To correct for multiple testing, the Bonferroni
9 method was utilized in the analysis for each of the above three types of pQTLs.

10 *Colocalization*

11 Results that passed the multiple-testing threshold in the above MR analysis were further
12 evaluated using the Bayesian colocalization analysis to estimate the posterior probability (PP)
13 of each genomic locus containing a single variant affecting both the protein abundance and
14 AD risk³³. Colocalization assesses whether two associated signals are consistent with a
15 common causal SNP. Default prior probabilities were used ($P_1 = 1 \times 10^{-4}$, $P_2 = 1 \times 10^{-4}$, $P_{12} =$
16 1×10^{-5} , where P_1 is the probability that a given SNP is associated with AD, P_2 is the
17 probability that a given SNP is a pQTL, and P_{12} is the probability that a given SNP is both
18 associated with AD and is a pQTL). We applied a PP threshold of >80% for the hypothesis
19 that there is a shared causal SNP for both traits as sufficient evidence for colocalization.

20 In cases where pQTL data lacked sufficient SNP coverage (e.g., without publicly available
21 full summary data), we instead conducted the “LD check” analysis⁵ for the sentinel variant
22 for each protein against the 30 strongest SNPs in the region associated with AD as an
23 approximate colocalization analysis. $r^2 > 0.8$ between the sentinel variant and any of the 30
24 SNPs with the strongest association with AD was used as evidence for approximate

1 colocalization. For our MR top findings, we treated colocalized findings (PP > 80%) as
2 “Colocalized” and LD-checked findings ($r^2 > 0.8$) as “LD-checked”; other findings that did
3 not pass the colocalization or LD check analyses were annotated as “Not colocalized”.

4 The presence of multiple conditionally distinct association signals within the same genomic
5 region can influence the performance of colocalization analysis ⁵. For regions with multiple
6 conditionally independent pQTLs, we performed pair-wise conditional and colocalization
7 analysis (PWCoCo) ³⁴ to obtain colocalization results. PWCoCo conducts conditional
8 analyses to identify independent signals for the two tested traits in a genomic region and then
9 conducts colocalization of each pair of conditionally independent signals for the two traits
10 using summary-level data, which allows for the stringent single-variant assumption to hold
11 for each pair of colocalization analyses.

12 For the top findings of our MR analysis, we performed colocalization analysis and LD check
13 on single-*cis*-pQTLs with and without full summary data available, respectively, and
14 PWCoCo on multiple-*cis*-pQTLs. For *cis* + *trans*-pQTLs, we performed colocalization
15 analysis on the *cis* instruments only.

16 *MR sensitivity analyses*

17 For multiple-*cis*- and *cis* + *trans*-pQTL MR top findings, we conducted Cochran’s Q test ³⁵
18 to assess heterogeneity across instrumental SNPs and the MR-Egger intercept test ³⁶ to detect
19 unbalanced horizontal pleiotropy. Where the protein did not have an enough number of pQTL
20 instruments in our original pQTL data, we used the data from a recent pQTL study by
21 Gudjonsson et al. ¹⁷ to conduct these analyses.

22 To reveal the directionality of effects and avoid reverse causation, we performed Steiger
23 filtering (for all top findings) and bidirectional MR (for those with full summary data

1 available from pQTL studies). Steiger filtering estimates the causal direction by comparing
2 the magnitude of variance explained by the exposure and the outcome³⁷. Bidirectional MR
3 evaluates the evidence for causal effects in the reverse direction by modeling AD as the
4 exposure and plasma proteins as the outcome. Instrumental SNPs for AD were selected based
5 on a threshold of $P < 5 \times 10^{-8}$ from GWAS after LD clumping ($r^2 < 0.001$ and distance
6 located 10000 kb apart from each other). The IVW method³² was used to evaluate the effect
7 of AD on plasma proteins. Where full summary statistics were not available in our original
8 pQTL data, we used full summary data from the pQTL study by Gudjonsson et al. to conduct
9 bidirectional MR analysis.

10 In addition, we also conducted a single-SNP MR analysis for multiple-*cis*-pQTLs, treating
11 each pQTL as a single instrumental SNP. Results for any novel top-hit proteins (i.e., not
12 included in the main top findings) that survived Bonferroni correction would be picked back
13 to the single-*cis*-pQTL analysis above.

14 *Replication*

15 To evaluate the reliability of our proteome-wide MR findings, we repeated MR analysis for
16 the top-hit proteins with the following combinations of exposure-outcome GWASes: 1)
17 Zheng et al. – Schwartzentruber et al., 2) Zheng et al. – Kunkle et al., 3) Gudjonsson et al. –
18 Bellenguez et al., and 4) Zheng et al. – Wightman et al. In each combination, the exposure
19 and outcome GWAS samples were both of European ancestry and did not overlap with each
20 other.

21 *Multi-omic validation*

22 We validated our top findings on transcriptomic and epigenomic layers in both blood and
23 brain using summary-data-based Mendelian randomization (SMR) followed by the

1 heterogeneity in dependent instruments (HEIDI) test³⁸. SMR aims to test the potential causal
2 effect of molecular traits on a complex trait of interest using summary data of QTL studies
3 and GWASes. The HEIDI test seeks to address if many SNPs in a single region give Wald
4 ratio estimates that are more different from each other than expected by chance under the
5 assumption that there is a single causal variant, and each SNP only exhibits an effect due to
6 LD with the causal SNP. SMR and the HEIDI test were performed with the above eQTL,
7 sQTL, or mQTL data as the exposure GWAS data and Bellenguez et al.'s AD GWAS data as
8 the outcome GWAS data.

9 We evaluated multi-omic validation results, along with the previous proteome-wide MR
10 results, using the following criteria:

- 11 1) On the proteomic layer, we first selected plasma proteins whose MR results passed the
12 Bonferroni correction for multiple testing (i.e., the top-hit proteins); then, we assessed if these
13 results showed colocalization evidence (i.e., either colocalized or LD-checked).
- 14 2) On the transcriptomic layer (i.e., gene expression), we first assessed if any *cis*-eQTL MR
15 results for the genes coding these proteins had a p-value < 0.05 in either blood or brain; if yes,
16 we evaluated if they passed the HEIDI test (i.e., $P_{\text{HEIDI}} > 0.05$); if they did, we checked if
17 their effect directions were plausible (i.e., whether the effect of the gene expression level was
18 in the same direction as that of the protein).
- 19 3) On the alternative splicing layer, we first assessed if any *cis*-sQTL MR results for the
20 alternative splicing of RNA related to these proteins had a p-value < 0.05 in either blood or
21 brain; if yes, we evaluated if they passed the HEIDI test. The plausibility of effect directions
22 was not considered, as there is no expected direction of the effect of alternative splicing on its
23 downstream protein products.

1 4) On the epigenomic layer (i.e., DNAm), we first assessed if any *cis*-mQTL MR results for
2 the DNAm in/near the genes coding these proteins had a p-value < 0.05 in either blood or
3 brain; if yes, then we evaluated if they passed the HEIDI test; if they did, then we examined if
4 the CpG sites were located in the promoter area of the gene by manually looking them up on
5 Ensembl (<https://www.ensembl.org/>); if the CpG sites were in the promoter area, we checked
6 if their effect directions were plausible (i.e., whether the effect of the DNAm level was in the
7 opposite direction to that of the protein).

8 Given the current availability of QTL data in the multi-omic validation stage and the wide
9 use of targeting drugs³⁹ that provided an opportunity to further explore clinical implications,
10 we followed up on ACE on top of the other top-hit proteins and conducted additional
11 analyses such as multivariable MR for this protein and conventional observational analysis
12 for the medication targeting it.

13 *Multivariable Mendelian randomization*

14 Given the important role of ACE (one of the top-hit proteins identified in proteome-wide MR)
15 in blood pressure regulation, we utilized multivariable MR⁴⁰ to explore if the effect of ACE
16 was dependent on blood pressure. As the pQTL study for ACE used in our main MR analysis
17 did not share full summary data⁴¹, we instead employed the pQTL data by Gudjonsson et al.
18¹⁷ used in our replication analysis. To avoid sample overlap, we used the AD GWAS by
19 Kunkle et al.²⁰ as the outcome GWAS, which did not include the UK Biobank samples used
20 for SBP/DBP GWASes. Separate multivariable MR models were applied to SBP and DBP,
21 respectively. SNPs related to SBP/DBP were selected from each GWAS dataset with the *p*-
22 value threshold of 5×10^{-8} and combined with the instrumental SNPs for ACE. Genetic
23 association data with ACE and SBP/DBP were extracted for each SNP, followed by
24 deduplication and LD clumping. A total of 244 SBP-related SNPs and 263 DBP-related SNPs,

1 respectively, in addition to the 6 pQTLs for ACE, were included in the multivariable MR
2 analysis. Multivariable MR inverse variance-weighted (MVMR-IVW) estimates⁴² were
3 computed for each model.

4 *Conventional observational study*

5 To further support our MR findings for the protein ACE in the “real-world” setting, we
6 conducted an observational study in the UK Biobank⁴³ to examine the association between
7 the regular use of ACEIs and the risk of AD in later life. Considering potential confounding
8 by indications, regular users of ARBs, another type of antihypertensive with similar
9 indications as ACEIs, were used as the reference group.

10 Baseline characteristics were presented as frequency (percentage) for categorical variables
11 and mean (SD) for continuous variables. Cox proportional hazards models were applied to
12 examine the longitudinal association between the regular use of ACEIs at baseline and the
13 incidence of AD, with regular use of ARBs as the reference. Three sets of models were
14 performed in the analysis: Model 1 was adjusted for age at recruitment, sex, and ethnicity;
15 Model 2 was additionally adjusted for hypertension, diabetes, hyperlipidemia, traumatic brain
16 injury, cerebrovascular diseases, and nervous system diseases; Model 3 was further adjusted
17 for smoking status, alcohol consumption frequency, BMI, income score, and educational
18 score. Considering that ACEIs and ARBs are primarily used as the treatment of hypertension,
19 we also restricted our analysis to participants with hypertension and repeated the analysis
20 using the aforementioned three models.

21 In addition, we performed the following sensitivity analyses to test the robustness of our
22 findings: 1) to minimize reverse causality, we excluded the participants who developed AD
23 during the first 2 years of follow-up; 2) considering the potential impact of other chronic

1 diseases, we further adjusted for the number of long-term conditions ²⁶; 3) we repeated the
2 analysis after excluding participants with baseline hyperlipidemia and diabetes, respectively.

3 *Analysis software*

4 The majority of MR analyses (including Wald ratio, IVW, single-SNP analysis, bidirectional
5 MR, Steiger filtering, and the heterogeneity and pleiotropy tests) were conducted using the
6 “TwoSampleMR” R package ²⁸. The IVW analysis considering LD patterns (i.e., generalized
7 IVW) was conducted using the “MendelianRandomization” R package ³¹. The MVMR
8 analysis was conducted by the “MVMR” R package ⁴⁴. Colocalization analysis was
9 conducted by the “coloc” R package ³³ and the “PWCoCo” tool ([https://github.com/jwr-](https://github.com/jwr-git/pwcoco)
10 [git/pwcoco](https://github.com/jwr-git/pwcoco)) ³⁴. SMR and HEIDI were performed by the “SMR” software tool (version 1.3.1;
11 downloaded from: <https://yanglab.westlake.edu.cn/software/smr/#Download>) ³⁸. Cox
12 proportional hazards analysis was performed using Stata 17 (Stata Corp. LP, College Station,
13 TX).

14 *Data availability*

15 Mendelian randomization and other relevant analyses were based on publicly available data,
16 for example, from publications by Zheng et al. (<https://doi.org/10.1038/s41588-020-0682-6>),
17 Bellenguez et al. (<https://doi.org/10.1038/s41588-022-01024-z>), Schwartzentruber et al.
18 (<https://doi.org/10.1038/s41588-020-00776-w>), Wightman et al.
19 (<https://doi.org/10.1038/s41588-021-00921-z>), Kunkle et al. ([https://doi.org/10.1038/s41588-](https://doi.org/10.1038/s41588-019-0358-2)
20 [019-0358-2](https://doi.org/10.1038/s41588-019-0358-2)), and Gudjonsson et al. (<https://doi.org/10.1038/s41467-021-27850-z>), as well as
21 data resources such as eQTLGen (<https://www.eqtlgen.org/>), BrainMeta
22 (https://yanglab.westlake.edu.cn/data/SMR/BrainMeta_v1.tar.gz;
23 https://yanglab.westlake.edu.cn/data/SMR/BrainMeta_cis_sqtl_summary.tar.gz), GTEx

1 (<https://www.gtexportal.org/>), GoDMC (<http://mqtl.db.godmc.org.uk/>), Brain-mMeta
2 (<https://yanglab.westlake.edu.cn/data/SMR/Brain-mMeta.tar.gz>), and IEU OpenGWAS
3 Project (<http://gwas.mrcieu.ac.uk/>). Conventional observational analysis corresponds to UK
4 Biobank Project ID 75283. Data from the UK Biobank are available at
5 <https://biobank.ndph.ox.ac.uk/> by application. The included GWASes had obtained the
6 necessary ethical approvals from the relevant committees and written informed consent was
7 obtained from all individuals involved in these studies. The UK Biobank study protocol was
8 approved by the North West Multi-centre Research Ethics Committee (11/NW/0382).

9 **RESULTS**

10 **Proteome-wide MR analysis**

11 After removing proteins with *trans*-only instruments and harmonizing with the summary data
12 from the outcome GWAS data, we obtained 593 single-*cis* pQTL instruments for 593
13 proteins, 298 multiple-*cis* pQTL instruments for 124 proteins, and 182 *cis* + *trans* pQTL
14 instruments for 73 proteins. A total of eight [granulin (GRN), angiotensin-converting enzyme
15 (ACE), complement decay-accelerating factor (CD55), triggering receptor expressed on
16 myeloid cells 2 (TREM2), transmembrane protein 106B (TMEM106B), leukocyte
17 immunoglobulin-like receptor B1 (LILRB1), signal-regulatory protein alpha (SIRPA), and
18 sialic acid-binding immunoglobulin-like lectin 9 (SIGLEC9)], five [alpha-L-iduronidase
19 (IDUA), leukocyte immunoglobulin-like receptor B2 (LILRB2), transcobalamin II (TCN2),
20 cathepsin H (CTSH), and glypican 5 (GPC5)], and two [leukocyte immunoglobulin-like
21 receptor A4 (LILRA4) and interleukin 6 signal transducer (IL6ST)] proteins passed the
22 Bonferroni correction (based on the total number of proteins available in each analysis: 593,
23 124, and 73, respectively) in the MR analysis for single-*cis*, multiple-*cis*, and *cis* + *trans*
24 pQTL instruments, respectively (**Table 1**). Specifically, among these 15 top-hit proteins, we

1 found evidence [odds ratio (OR) and 95% confidence interval (CI)] of genetically predicted
2 higher plasma GRN [0.79 (0.74-0.84)], ACE [0.91 (0.88-0.93)], CD55 [0.90 (0.86-0.93)],
3 TREM2 [0.67 (0.58-0.78)], LILRB1 [0.95 (0.93-0.97)], TCN2 [0.98 (0.97-0.99)], and
4 LILRA4 [0.89 (0.85-0.95)] levels being associated with lower AD risk, and evidence of
5 genetically predicted higher plasma TMEM106B [1.16 (1.09-1.23)], SIRPA [1.03 (1.02-
6 1.05)], SIGLEC9 [1.03 (1.02-1.04)], IDUA [1.06 (1.05-1.08)], LILRB2 [1.04 (1.02-1.06)],
7 CTSH [1.05 (1.02-1.07)], GPC5 [1.04 (1.02-1.05)], and IL6ST [1.09 (1.04-1.14)] levels being
8 associated with higher AD risk (**Table 1**).

9 **Colocalization analysis**

10 Among the eight proteins with single-*cis* pQTLs (four with full summary data available),
11 only GRN showed colocalization evidence (PP for a shared causal variant = 99.4%, **Table 1**,
12 **Figure S1**). In the absence of full summary data or colocalization evidence detected by
13 colocalization analysis, LD check revealed evidence for approximate colocalization for ACE,
14 CD55, TREM2, TMEM106B, LILRB1, and SIRPA (**Table 1**). For the five proteins with
15 multiple-*cis* pQTLs, PWCoCo showed colocalization evidence for IDUA (**Table 1**). For the
16 two proteins with *cis* + *trans* pQTLs, colocalization analysis (on the *cis*-pQTL only) failed to
17 find evidence for colocalization in either protein. See regional plots of all proteins with full
18 GWAS summary statistics in **Figure S1-S11**.

19 When using the data from a recent pQTL study by Gudjonsson et al.,¹⁷ where full summary
20 statistics were available for ACE, TREM2, TMEM106B, and SIRPA, colocalization evidence
21 was found for ACE and TMEM106B (**Table S1**).

22 **Multi-omics validation and selection of top findings**

1 Detailed SMR and HEIDI results are shown in **Table S2-S7**. Of the 15 top-hit plasma
2 proteins that passed the Bonferroni correction threshold, GRN, ACE, CD55, TREM2,
3 TMEM106B, LILRB, SIRPA, IDUA, and TCN2 showed evidence for colocalization
4 (including approximate colocalization detected by LD-check); in the blood/brain *cis*-eQTL
5 SMR analysis, the expression of three genes (*ACE*, *SIGLEC9*, and *IDUA*) was associated
6 with AD risk at the $P = 0.05$ level, passed the HEIDI test (i.e., $P_{\text{HEIDI}} > 0.05$), and had
7 plausible effect directions (i.e., in the same direction as the pQTL MR results); in the
8 blood/brain *cis*-sQTL SMR analysis, alternative splicing in five genes (*ACE*, *TMEM106B*,
9 *SIRPA*, *SIGLEC9*, and *IDUA*) was associated with AD risk at the $P = 0.05$ level and passed
10 the HEIDI test; in the blood/brain *cis*-mQTL SMR analysis, we only found that DNAm in the
11 *ACE* gene was associated with AD risk at the $P = 0.05$ level, passed the HEIDI test, was
12 located in the promoter area of the gene (cg06751221, 17:63477520-63477569), and had a
13 plausible effect direction (i.e., in the opposite direction as the pQTL MR results) (**Figure 2**,
14 **Table 2**; see detailed sQTL MR results in **Figure S12-S13**). It should also be noted that
15 validation analyses were not always applicable due to the unavailability of QTL data for
16 some proteins.

17 Given the current availability of QTL data in the multi-omic validation stage and the wide
18 use of targeting drugs³⁹ that provided an opportunity to further explore clinical implications,
19 we followed up on ACE (angiotensin-converting enzyme) on top of the other 14 top-hit
20 proteins and conducted additional analyses such as multivariable MR for this protein and
21 observational analysis for the medication targeting it.

22 **MR sensitivity analyses**

23 We conducted a range of sensitivity and replication analyses to test the robustness and
24 reliability of our MR findings. For ACE specifically (see other proteins in **Text S1**), our

1 sensitivity analyses did not find evidence for reverse causation as detected by Steiger filtering,
2 whereas Cochran's Q test, MR-Egger intercept test, and bidirectional MR were not applicable
3 as ACE had only one pQTL instrument and its GWAS full summary statistics were not
4 available. Where these sensitivity analyses were not applicable due to the insufficient number
5 of instruments or the unavailability of full summary data, we used the data from a recent
6 pQTL study by Gudjonsson et al. (where multiple pQTL instruments and full summary
7 statistics were available) and found no evidence for heterogeneity (by Cochran's Q test),
8 pleiotropy (by MR-Egger intercept test), or reverse causation (by bidirectional MR) for ACE
9 (**Table S1**). See the detailed description of sensitivity analysis results (including single-SNP
10 analysis results in **Table S8**) for other top-hit proteins in **Text S1**.

11 In replication analyses, we used data from different pQTL studies and GWASes to replicate
12 our MR top findings. We first used an earlier AD GWAS by Schwartzentruber et al. [0.93
13 (0.90-0.96)] and Wightman et al. [0.987 (0.981-0.992)] and then a smaller but more clinically
14 relevant AD GWAS by Kunkle et al. (only included clinically diagnosed AD cases) [0.92
15 (0.88-0.97)] as the outcome GWAS and observed similar results in effect directions and sizes
16 for ACE (**Table S9, Figure S14**). Then, we replaced our original pQTL data with those from
17 a recently published GWAS of 2,091 serum proteins by Gudjonsson et al. and also found that
18 ACE had a similar effect estimate [0.93 (0.90-0.97)] as our main MR results (**Table S9,**
19 **Figure S14**). See the detailed description of replication analysis results for other top-hit
20 proteins in **Text S1**.

21 Our multivariable MR showed that after adjusting for SBP or DBP, the effect estimate of
22 ACE did not differ from our univariable (i.e., main) MR results (**Table S10, Figure S15**),
23 suggesting that the protective effect of ACE on AD risk was likely independent of blood
24 pressure.

1 **Observational analysis of ACE inhibitor use**

2 From the pQTL MR analysis above, we found a protective effect of higher plasma ACE
3 levels on AD risk [OR (95% CI): 0.91 (0.88-0.93)], suggesting that ACE inhibition (i.e.,
4 inhibiting the effect of ACE) might be potentially associated with an increased risk of AD
5 [OR (95% CI): 1.10 (1.08-1.14), estimated by taking the inverse of the ACE effect]. To
6 follow up on this finding and explore its clinical relevance, we used “real-world” drug use
7 data of ACE inhibitors (ACEIs, with ACE inhibition effects) from the UK Biobank and
8 examined if ACEI use was associated with increased AD risk. ACEIs are a commonly used
9 antihypertensive in clinical practice and the only existing class of drugs targeting ACE. To
10 avoid potential confounding by indications, we used angiotensin receptor blockers (ARBs),
11 which have similar indications but different drug targets as ACEIs, as the reference for the
12 comparison.

13 A total of 59,117 UK Biobank participants were included in the study, including 42,944
14 ACEI users and 16,173 ARB users. At baseline, the mean age was 60.4 (standard deviation
15 6.6) years [60.2 (6.7) years in ACEI users vs. 61.0 (6.4) years in ARB users], and 41% of the
16 participants were female (38.3% in ACEI users vs. 48.3% in ARB users; see **Table S11**).
17 Over 723,142 person-years of follow-up [median (interquartile range) length of follow-up:
18 12.77 (11.92–13.54) years], there were 552 cases of AD, with 0.97% (416/42,944) in ACEI
19 users and 0.84% (136/16,173) in ARB users.

20 Analysis with Cox proportional hazard models showed a higher incidence of AD in ACEI
21 users compared with ARB users [hazard ratio (95% CI): 1.24 (1.01-1.52)] (**Figure 3**), with
22 adjustment for age at recruitment, sex, ethnicity, pre-existing morbidities (hypertension,
23 diabetes, hyperlipidemia, cerebrovascular diseases, traumatic brain injury, and diseases of the
24 nervous system), smoking status, alcohol use, body mass index, income, and educational.

1 When restricting to participants with hypertension, the results were consistent [1.31 (1.01-
2 1.69)] (**Figure 3**). Moreover, no major changes in the results were found in sensitivity
3 analyses excluding cases with baseline diabetes or hyperlipidemia, additionally adjusting for
4 the number of baseline chronic conditions, or removing AD cases occurring within the first
5 two years of follow-up (**Figure S16**).

6 Given the MR evidence suggesting that inhibition of ACE might increase the risk of AD, the
7 higher AD risk associated with the regular use of ACEIs (which inhibit ACE activity) vs.
8 their counterpart ARBs (block angiotensin II receptors) observed in the UK Biobank
9 complements our MR findings and provides further evidence for the implications of these
10 findings in clinical settings (**Figure 4**).

11 **DISCUSSION**

12 In this study, we conducted a proteome-wide MR analysis, which identified 15 plasma
13 proteins associated with AD risk, including ACE, GRN, CD55, TREM2, TMEM106B,
14 LILRB1, SIRPA, SIGLEC9, IDUA, LILRB2, TCN2, CTSH, GPC5, LILRA4, and IL6ST,
15 followed by validation on the transcriptomic and epigenomic layers. Of these proteins,
16 inhibition of ACE was suggested to increase the risk of AD, which was likely independent of
17 blood pressure. Given the availability of QTL data in the multi-omic validation stage and the
18 popularity of relevant drugs, we further explored the clinical implications of ACE and its
19 targeting drugs. As a classic antihypertensive medication inhibiting ACE activity in “real-
20 world” settings, ACEIs were observationally associated with an increased risk of AD as
21 compared with ARBs, another antihypertensive with similar indications but different targets,
22 in the UK Biobank, which complements our MR results.

1 Our findings generally align with and expand upon prior research on proteins as potential
2 druggable targets for preventing AD. For example, a recent study by Ou et al. applied similar
3 methodologies (e.g., proteome-wide MR, colocalization, and eQTL MR) to explore potential
4 AD drug targets by integrating genetics and proteomes from the brain and blood ⁶. They
5 identified seven genes (*ACE*, *ICAIL*, *TOMIL2*, *SNX32*, *EPHX2*, *CTSH*, and *RTFDC1*) with
6 brain protein abundance causally linked to AD. Among these, the protective effect of *ACE*
7 was substantiated by both proteomic and transcriptomic evidence in blood. Our study, which
8 yielded comparable results for *ACE*, provides robust support for their findings by discovering
9 consistent evidence supporting our MR findings for *ACE* from observational analysis of
10 “real-world” drug use data, addressing the methodological limitations of using a single
11 epidemiologic approach ⁴⁵ and underscoring the implications of our findings for clinical
12 practice. Moreover, we also leveraged larger and more recent GWAS data, verified the
13 reliability of findings across multiple pQTL studies and AD GWASes, and further validated
14 the findings at the alternative splicing and DNA methylation levels. Additionally, despite not
15 having brain pQTL data, our study still supports their finding for *CTSH* by providing
16 stronger evidence in blood. To sum up, Ou et al.’s and our studies serve as complementary
17 pieces, collectively contributing to drug discovery, repurposing, and vigilance efforts for AD.

18 Specifically, the protective effect of the protein *ACE* against AD is a noteworthy finding in
19 both Ou et al.’s and our studies that warrants further discussion. While previous genetic and
20 epidemiologic studies have reported similar associations ^{6, 46-48}, our work provides deeper
21 insights into the potential mechanisms underlying the relationship between *ACE* and AD risk.
22 *ACE* is well-known for its biological functions, such as its involvement in the renin-
23 angiotensin system (RAS), which plays a crucial role in regulating blood pressure ⁴⁹.
24 However, our multivariable MR results suggest that the effect of *ACE* on AD risk seemed to
25 be independent of blood pressure. In our observational analysis of prospective cohort data, a

1 difference in AD risk was also observed between users of ACEIs and ARBs, which both
2 target the RAS but act on different molecules (ACEIs inhibit the angiotensin-converting
3 enzyme, while ARBs block angiotensin II receptors, as shown in **Figure 4**)⁵⁰. All these
4 findings suggest that ACE may influence neurodegenerative diseases through unique
5 pathways other than blood pressure regulation⁵¹. One such potential mechanism is the
6 degradation of amyloid-beta (A β) deposits. ACE is a component of A β -degrading enzymes
7 (ADEs) and can facilitate the clearance of A β deposits, which are implicated in the
8 pathogenesis of AD⁵².

9 The discovery that ACEI use was associated with increased AD risk raises important
10 questions for clinical and public health practice. ACEIs and ARBs are both widely used first-
11 line antihypertensives, which are usually recommended interchangeably by current guidelines
12⁵³. In the United States alone, 13.5 million people take ARBs and 19.1 million take ACEIs
13 each year⁵⁴. Although only a 20-30% increased AD risk associated with ACEI use was
14 observed in our study, considering the huge number of ACEI users and the increasingly
15 heavy burden of AD¹, its public health implications are substantial on a global scale. If our
16 findings can be confirmed by high-quality clinical trials, switching first-line RAS blockers
17 from ACEIs to ARBs may have a great impact on population health. Preferentially
18 prescribing ARBs over ACEIs is also supported by a recent statement by Messerli et al.³⁹
19 and a large study⁵⁵ of 2,297,881 patients initiating treatment with ACEIs and 673,938
20 patients with ARBs, which has found that while ACEIs and ARBs have similar efficacy in
21 reducing the risk of cardiovascular events, ARB users have better safety outcomes such as
22 lower risks of angioedema, cough, and gastrointestinal conditions. In addition, further
23 research is needed to elucidate the complex relationship between ACE, blood pressure, other
24 antihypertensive medications, and AD risk, and to determine the potential impact of these
25 findings on the management of hypertension and prevention strategies for AD. Our findings

1 highlight the need to carefully consider the potential risks and benefits of ACEIs and other
2 antihypertensive medications in the context of neurodegenerative diseases.

3 Several other proteins identified in our study have been previously linked to the pathogenesis
4 of AD or other neurodegenerative diseases by in-vivo and in-vitro studies. For example,
5 granulin (GRN) and triggering receptor expressed on myeloid cells 2 (TREM2) have been
6 shown to play a role in microglial function and neuroinflammation⁵⁶⁻⁵⁸, which are key
7 processes in AD development⁵⁹. Other identified proteins, such as CD55 and TMEM106B,
8 have also been reported to have potential roles in AD-related pathways, including immune
9 response and cellular homeostasis. The protein CD55 has been shown to mitigate neuronal
10 cell death and apoptosis during hypoxia induced by sodium cyanide⁶⁰. A study of aged mice
11 with *Tmem106b* knockout, heterozygote, and wild-type genotypes found that TMEM106B-
12 dependent lysosomal trafficking defects led to neuronal dysfunction and behavioral
13 impairments⁶¹. Therefore, our findings for other top-hit proteins warrant further
14 investigations into their mechanistic contributions to AD and their potential value as drug
15 targets for AD prevention.

16 Our study has several strengths, one of which is the application of a proteome-wide MR
17 approach. This method enabled us to systematically evaluate the effects of plasma proteins on
18 AD risk while minimizing the influence of confounding and reverse causation. By integrating
19 multiple omic layers, including proteomic, transcriptomic, epigenomic, and genomic data, we
20 provided comprehensive evidence to support the reliability of our results. Importantly, we
21 also combined MR with observational analysis of prospective cohort data, establishing a
22 connection between molecule-level research and “real-world” clinical evidence, which
23 strengthens the clinical relevance of our findings.

1 Despite these strengths, our study also has the following limitations. First, although MR is a
2 powerful approach for addressing confounding, it cannot eliminate the possibility of
3 horizontal pleiotropy⁶², and the MR methods we used could only examine the linear
4 relationship between the protein level and AD risk. Second, our study only assessed proteins
5 with available genetic instruments of relatively high reliability (i.e., tier 1 instruments in
6 Zheng et al.'s study)⁵, which may have excluded other potentially relevant proteins in the
7 context of AD pathogenesis. Similarly, an additional limitation is the absence of QTL data
8 (e.g., mQTL data in blood and brain) for some top-hit proteins, which precluded our follow-
9 up analyses on many potentially relevant results. Fourth, as our study predominantly included
10 participants of European descent, the generalizability of our findings to other populations
11 remains uncertain. It is essential to validate our results in diverse ethnic groups to better
12 understand the applicability of our findings across different populations⁶³. Another limitation
13 is the potential of residual confounding in our observational analysis due to unmeasured or
14 inaccurately measured confounders, although the consistency between observational and MR
15 evidence mitigates this concern to some extent. In addition, our observational analysis with
16 baseline drug use as the exposure (i.e., prevalent users) may be subject to selection bias, and
17 future research can explore the effect of initiation, maintenance, or discontinuation of ACEI
18 use on AD risk by explicitly emulating a target trial using observational data⁶⁴. Selection bias
19 might also occur when restricting our observational analysis to ACEI and ARB users,
20 although this restriction was justified to avoid confounding by indication. Lastly, while we
21 were able to identify some proteins with possible causal effects on AD risk, it is important to
22 recognize that these proteins may not be acting independently. The complex interplay
23 between these proteins and their roles in various biological pathways could contribute to the
24 observed associations, warranting further investigation to fully elucidate the intricate network
25 of molecular mechanisms underlying AD pathogenesis.

1 In conclusion, our proteome-wide MR study identified 15 plasma proteins associated with
2 AD risk. Of these, ACE inhibition was suggested to increase the risk of AD. Observationally,
3 the regular use of ACEIs, a common class of antihypertensive inhibiting the effect of ACE,
4 was associated with an increased risk of AD as compared with ARBs, another
5 antihypertensive with similar indications but different molecular targets. While this key
6 finding warrants further investigation, it underscores the need to carefully consider potential
7 implications in terms of neurodegenerative diseases when prescribing ACEIs for high-risk
8 populations and add support to the preferential prescription of ARBs over ACEIs in clinical
9 practice. Our work also highlights the clinical translatability of interdisciplinary research
10 integrating genetic/omics-based approaches with “real-world” data in the field of pharmaco-
11 epidemiology.

12 **ACKNOWLEDGMENTS**

13 We thank all participants and researchers from GWAS consortia, QTL databases, and the UK
14 Biobank.

15 **SOURCES OF FUNDING**

16 This work was supported by grants from the National Key Research and Development
17 Program of China (2022YFC2505203, 2022YFC3602400, 2022YFC3602401), National
18 Natural Science Foundation of China (82170437), Central South University Innovation-
19 Driven Research Program (2023CXQD007). JZ is a member of the Innovative Research
20 Team of High-level Local Universities in Shanghai. TRG and ES work at a unit that receives
21 funding from the University of Bristol and the UK Medical Research Council
22 (MC_UU_00011/1, MC_UU_00032/01, MC_UU_00032/03 and MC_UU_00011/4). T.R.G.
23 also holds a Turing Fellowship from the Alan Turing Institute. PH is funded by Wellcome

1 Trust PhD Studentship in Molecular, Genetic and Lifecourse Epidemiology (224979/Z/22/Z).
2 The funding sources were not involved in the study design, the interpretation of data, the
3 writing of the report, and the decision to submit the article for publication.

4 **DISCLOSURES**

5 Tom R Gaunt declares that he receives funding from Biogen for other research not
6 represented in this manuscript, while other authors declare no conflict of interest.

7 **REFERENCES**

- 8 1. World Health Organization. Dementia. 2023.
- 9 2. Alzheimer's Disease International. World Alzheimer Report 2018. 2018.
- 10 3. Jack CR, Jr. Advances in Alzheimer's disease research over the past two decades. *Lancet*
11 *Neurol.* 2022;21:866-9. doi:10.1016/s1474-4422(22)00298-8
- 12 4. Wang ZB, Wang ZT, Sun Y, Tan L, Yu JT. The future of stem cell therapies of Alzheimer's
13 disease. *Ageing Res Rev.* 2022;80:101655. doi:10.1016/j.arr.2022.101655
- 14 5. Zheng J, Haberland V, Baird D, Walker V, Haycock PC, Hurler MR, et al. Phenome-wide
15 Mendelian randomization mapping the influence of the plasma proteome on complex diseases.
16 *Nature Genetics.* 2020;52:1122-31. doi:10.1038/s41588-020-0682-6
- 17 6. Ou Y-N, Yang Y-X, Deng Y-T, Zhang C, Hu H, Wu B-S, et al. Identification of novel drug
18 targets for Alzheimer's disease by integrating genetics and proteomes from brain and blood.
19 *Molecular Psychiatry.* 2021;26:6065-73. doi:10.1038/s41380-021-01251-6
- 20 7. Wingo AP, Liu Y, Gerasimov ES, Gockley J, Logsdon BA, Duong DM, et al. Integrating
21 human brain proteomes with genome-wide association data implicates new proteins in
22 Alzheimer's disease pathogenesis. *Nature Genetics.* 2021;53:143-6. doi:10.1038/s41588-020-
23 00773-z
- 24 8. Yang C, Farias FHG, Ibanez L, Suhy A, Sadler B, Fernandez MV, et al. Genomic atlas of the
25 proteome from brain, CSF and plasma prioritizes proteins implicated in neurological
26 disorders. *Nature Neuroscience.* 2021;24:1302-12. doi:10.1038/s41593-021-00886-6
- 27 9. Ge YJ, Ou YN, Deng YT, Wu BS, Yang L, Zhang YR, et al. Prioritization of Drug Targets
28 for Neurodegenerative Diseases by Integrating Genetic and Proteomic Data From Brain and
29 Blood. *Biol Psychiatry.* 2023;93:770-9. doi:10.1016/j.biopsych.2022.11.002
- 30 10. Swerdlow DI, Kuchenbaecker KB, Shah S, Sofat R, Holmes MV, White J, et al. Selecting
31 instruments for Mendelian randomization in the wake of genome-wide association studies. *Int*
32 *J Epidemiol.* 2016;45:1600-16. doi:10.1093/ije/dyw088
- 33 11. Bellenguez C, Küçükali F, Jansen IE, Kleindam L, Moreno-Grau S, Amin N, et al. New
34 insights into the genetic etiology of Alzheimer's disease and related dementias. *Nature*
35 *Genetics.* 2022;54:412-36. doi:10.1038/s41588-022-01024-z
- 36 12. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. The UK Biobank
37 resource with deep phenotyping and genomic data. *Nature.* 2018;562:203-9.
38 doi:10.1038/s41586-018-0579-z

- 1 13. Vösa U, Claringbould A, Westra HJ, Bonder MJ, Deelen P, Zeng B, et al. Large-scale cis-
2 and trans-eQTL analyses identify thousands of genetic loci and polygenic scores that regulate
3 blood gene expression. *Nat Genet.* 2021;53:1300-10. doi:10.1038/s41588-021-00913-z
- 4 14. Qi T, Wu Y, Fang H, Zhang F, Liu S, Zeng J, et al. Genetic control of RNA splicing and its
5 distinct role in complex trait variation. *Nature Genetics.* 2022;54:1355-63.
6 doi:10.1038/s41588-022-01154-4
- 7 15. Li YI, Knowles DA, Humphrey J, Barbeira AN, Dickinson SP, Im HK, et al. Annotation-free
8 quantification of RNA splicing using LeafCutter. *Nat Genet.* 2018;50:151-8.
9 doi:10.1038/s41588-017-0004-9
- 10 16. Qi T, Wu Y, Zeng J, Zhang F, Xue A, Jiang L, et al. Identifying gene targets for brain-related
11 traits using transcriptomic and methylomic data from blood. *Nat Commun.* 2018;9:2282.
12 doi:10.1038/s41467-018-04558-1
- 13 17. Gudjonsson A, Gudmundsdottir V, Axelsson GT, Gudmundsson EF, Jonsson BG, Launer LJ,
14 et al. A genome-wide association study of serum proteins reveals shared loci with common
15 diseases. *Nature Communications.* 2022;13:480. doi:10.1038/s41467-021-27850-z
- 16 18. Harris TB, Launer LJ, Eiriksdottir G, Kjartansson O, Jonsson PV, Sigurdsson G, et al. Age,
17 Gene/Environment Susceptibility-Reykjavik Study: multidisciplinary applied phenomics. *Am*
18 *J Epidemiol.* 2007;165:1076-87. doi:10.1093/aje/kwk115
- 19 19. Schwartzenuber J, Cooper S, Liu JZ, Barrio-Hernandez I, Bello E, Kumasaka N, et al.
20 Genome-wide meta-analysis, fine-mapping and integrative prioritization implicate new
21 Alzheimer's disease risk genes. *Nature Genetics.* 2021;53:392-402. doi:10.1038/s41588-020-
22 00776-w
- 23 20. Kunkle BW, Grenier-Boley B, Sims R, Bis JC, Damotte V, Naj AC, et al. Genetic meta-
24 analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates A β , tau,
25 immunity and lipid processing. *Nature Genetics.* 2019;51:414-30. doi:10.1038/s41588-019-
26 0358-2
- 27 21. Wightman DP, Jansen IE, Savage JE, Shadrin AA, Bahrami S, Holland D, et al. A genome-
28 wide association study with 1,126,563 individuals identifies new risk loci for Alzheimer's
29 disease. *Nat Genet.* 2021;53:1276-82. doi:10.1038/s41588-021-00921-z
- 30 22. Day FR, Loh PR, Scott RA, Ong KK, Perry JR. A Robust Example of Collider Bias in a
31 Genetic Association Study. *Am J Hum Genet.* 2016;98:392-3. doi:10.1016/j.ajhg.2015.12.019
- 32 23. Elsworth B, Lyon M, Alexander T, Liu Y, Matthews P, Hallett J, et al. The MRC IEU
33 OpenGWAS data infrastructure. *bioRxiv.* 2020:2020.08.10.244293.
34 doi:10.1101/2020.08.10.244293
- 35 24. World Health Organization. Anatomical Therapeutic Chemical (ATC) Classification.
- 36 25. World Health Organization. International Statistical Classification of Diseases and Related
37 Health Problems 10th Revision. 2019.
- 38 26. Wu Y, Xiong T, Tan X, Chen L. Frailty and risk of microvascular complications in patients
39 with type 2 diabetes: a population-based cohort study. *BMC Med.* 2022;20:473.
40 doi:10.1186/s12916-022-02675-9
- 41 27. Lawlor DA, Harbord RM, Sterne JA, Timpson N, Davey Smith G. Mendelian randomization:
42 using genes as instruments for making causal inferences in epidemiology. *Stat Med.*
43 2008;27:1133-63. doi:10.1002/sim.3034
- 44 28. Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, et al. The MR-Base
45 platform supports systematic causal inference across the human phenome. *Elife.* 2018;7.
46 doi:10.7554/eLife.34408

- 1 29. Burgess S, Dudbridge F, Thompson SG. Combining information on multiple instrumental
2 variables in Mendelian randomization: comparison of allele score and summarized data
3 methods. *Stat Med*. 2016;35:1880-906. doi:10.1002/sim.6835
- 4 30. Burgess S, Zuber V, Valdes-Marquez E, Sun BB, Hopewell JC. Mendelian randomization
5 with fine-mapped genetic data: Choosing from large numbers of correlated instrumental
6 variables. *Genet Epidemiol*. 2017;41:714-25. doi:10.1002/gepi.22077
- 7 31. Yavorska OO, Burgess S. MendelianRandomization: an R package for performing Mendelian
8 randomization analyses using summarized data. *Int J Epidemiol*. 2017;46:1734-9.
9 doi:10.1093/ije/dyx034
- 10 32. Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with multiple
11 genetic variants using summarized data. *Genet Epidemiol*. 2013;37:658-65.
12 doi:10.1002/gepi.21758
- 13 33. Giambartolomei C, Vukcevic D, Schadt EE, Franke L, Hingorani AD, Wallace C, et al.
14 Bayesian test for colocalisation between pairs of genetic association studies using summary
15 statistics. *PLoS Genet*. 2014;10:e1004383. doi:10.1371/journal.pgen.1004383
- 16 34. Robinson JW, Hemani G, Babaei MS, Huang Y, Baird DA, Tsai EA, et al. An efficient and
17 robust tool for colocalisation: Pair-wise Conditional and Colocalisation (PWCoCo). *bioRxiv*.
18 2022:2022.08.08.503158. doi:10.1101/2022.08.08.503158
- 19 35. Greco MF, Minelli C, Sheehan NA, Thompson JR. Detecting pleiotropy in Mendelian
20 randomisation studies with summary data and a continuous outcome. *Stat Med*.
21 2015;34:2926-40. doi:10.1002/sim.6522
- 22 36. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments:
23 effect estimation and bias detection through Egger regression. *International Journal of*
24 *Epidemiology*. 2015;44:512-25. doi:10.1093/ije/dyv080
- 25 37. Hemani G, Tilling K, Davey Smith G. Orienting the causal relationship between imprecisely
26 measured traits using GWAS summary data. *PLoS Genet*. 2017;13:e1007081.
27 doi:10.1371/journal.pgen.1007081
- 28 38. Zhu Z, Zhang F, Hu H, Bakshi A, Robinson MR, Powell JE, et al. Integration of summary
29 data from GWAS and eQTL studies predicts complex trait gene targets. *Nature Genetics*.
30 2016;48:481-7. doi:10.1038/ng.3538
- 31 39. Messerli FH, Bavishi C, Bangalore S. Why Are We Still Prescribing Angiotensin-Converting
32 Enzyme Inhibitors? *Circulation*. 2022;145:413-5. doi:10.1161/circulationaha.121.057835
- 33 40. Burgess S, Thompson SG. Multivariable Mendelian Randomization: The Use of Pleiotropic
34 Genetic Variants to Estimate Causal Effects. *American Journal of Epidemiology*.
35 2015;181:251-60. doi:10.1093/aje/kwu283
- 36 41. Emilsson V, Ilkov M, Lamb JR, Finkel N, Gudmundsson EF, Pitts R, et al. Co-regulatory
37 networks of human serum proteins link genetics to disease. *Science*. 2018;361:769-73.
38 doi:10.1126/science.aag1327
- 39 42. Sanderson E, Spiller W, Bowden J. Testing and correcting for weak and pleiotropic
40 instruments in two-sample multivariable Mendelian randomization. *Stat Med*. 2021;40:5434-
41 52. doi:10.1002/sim.9133
- 42 43. Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, et al. UK biobank: an open
43 access resource for identifying the causes of a wide range of complex diseases of middle and
44 old age. *PLoS Med*. 2015;12:e1001779. doi:10.1371/journal.pmed.1001779
- 45 44. Sanderson E, Davey Smith G, Windmeijer F, Bowden J. An examination of multivariable
46 Mendelian randomization in the single-sample and two-sample summary data settings. *Int J*
47 *Epidemiol*. 2019;48:713-27. doi:10.1093/ije/dyy262

- 1 45. Lawlor DA, Tilling K, Davey Smith G. Triangulation in aetiological epidemiology.
2 *International Journal of Epidemiology*. 2017;45:1866-86. doi:10.1093/ije/dyw314
- 3 46. Walker VM, Kehoe PG, Martin RM, Davies NM. Repurposing antihypertensive drugs for the
4 prevention of Alzheimer's disease: a Mendelian randomization study. *International Journal*
5 *of Epidemiology*. 2019;49:1132-40. doi:10.1093/ije/dyz155
- 6 47. Lehmann DJ, Cortina-Borja M, Warden DR, Smith AD, Slegers K, Prince JA, et al. Large
7 Meta-Analysis Establishes the ACE Insertion-Deletion Polymorphism as a Marker of
8 Alzheimer's Disease. *American Journal of Epidemiology*. 2005;162:305-17.
9 doi:10.1093/aje/kwi202
- 10 48. Li NC, Lee A, Whitmer RA, Kivipelto M, Lawler E, Kazis LE, et al. Use of angiotensin
11 receptor blockers and risk of dementia in a predominantly male population: prospective
12 cohort analysis. *Bmj*. 2010;340:b5465. doi:10.1136/bmj.b5465
- 13 49. Te Riet L, van Esch JH, Roks AJ, van den Meiracker AH, Danser AH. Hypertension: renin-
14 angiotensin-aldosterone system alterations. *Circ Res*. 2015;116:960-75.
15 doi:10.1161/circresaha.116.303587
- 16 50. Strauss MH, Hall AS. The Divergent Cardiovascular Effects of Angiotensin Converting
17 Enzyme Inhibitors and Angiotensin Receptor Blockers on Myocardial Infarction and Death.
18 *Prog Cardiovasc Dis*. 2016;58:473-82. doi:10.1016/j.pcad.2015.11.004
- 19 51. Kehoe PG, Miners S, Love S. Angiotensins in Alzheimer's disease - friend or foe? *Trends*
20 *Neurosci*. 2009;32:619-28. doi:10.1016/j.tins.2009.07.006
- 21 52. Hampel H, Hardy J, Blennow K, Chen C, Perry G, Kim SH, et al. The Amyloid- β Pathway in
22 Alzheimer's Disease. *Molecular Psychiatry*. 2021;26:5481-503. doi:10.1038/s41380-021-
23 01249-0
- 24 53. Whelton PK, Carey RM, Aronow WS, Casey DE, Jr., Collins KJ, Dennison Himmelfarb C, et
25 al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for
26 the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults:
27 Executive Summary: A Report of the American College of Cardiology/American Heart
28 Association Task Force on Clinical Practice Guidelines. *Circulation*. 2018;138:e426-e83.
29 doi:10.1161/cir.0000000000000597
- 30 54. Marcum ZA, Cohen JB, Larson EB, Williamson J, Bress AP. Can Preferentially Prescribing
31 Angiotensin II Receptor Blockers (ARBs) over Angiotensin-Converting Enzyme Inhibitors
32 (ACEIs) Decrease Dementia Risk and Improve Brain Health Equity? *NAM Perspect*.
33 2022;2022. doi:10.31478/202205c
- 34 55. Chen R, Suchard MA, Krumholz HM, Schuemie MJ, Shea S, Duke J, et al. Comparative
35 First-Line Effectiveness and Safety of ACE (Angiotensin-Converting Enzyme) Inhibitors and
36 Angiotensin Receptor Blockers: A Multinational Cohort Study. *Hypertension*. 2021;78:591-
37 603. doi:10.1161/hypertensionaha.120.16667
- 38 56. Lui H, Zhang J, Makinson SR, Cahill MK, Kelley KW, Huang HY, et al. Progranulin
39 Deficiency Promotes Circuit-Specific Synaptic Pruning by Microglia via Complement
40 Activation. *Cell*. 2016;165:921-35. doi:10.1016/j.cell.2016.04.001
- 41 57. Krabbe G, Minami SS, Etcheagaray JI, Taneja P, Djukic B, Davalos D, et al. Microglial
42 NF κ B-TNF α hyperactivation induces obsessive-compulsive behavior in mouse models of
43 progranulin-deficient frontotemporal dementia. *Proc Natl Acad Sci U S A*. 2017;114:5029-34.
44 doi:10.1073/pnas.1700477114
- 45 58. Chen S, Peng J, Sherchan P, Ma Y, Xiang S, Yan F, et al. TREM2 activation attenuates
46 neuroinflammation and neuronal apoptosis via PI3K/Akt pathway after intracerebral
47 hemorrhage in mice. *J Neuroinflammation*. 2020;17:168. doi:10.1186/s12974-020-01853-x

- 1 59. Leng F, Edison P. Neuroinflammation and microglial activation in Alzheimer disease: where
2 do we go from here? *Nat Rev Neurol*. 2021;17:157-72. doi:10.1038/s41582-020-00435-y
- 3 60. Wang Y, Li Y, Dalle Lucca SL, Simovic M, Tsokos GC, Dalle Lucca JJ. Decay accelerating
4 factor (CD55) protects neuronal cells from chemical hypoxia-induced injury. *J*
5 *Neuroinflammation*. 2010;7:24. doi:10.1186/1742-2094-7-24
- 6 61. Stroobants S, D'Hooge R, Damme M. Aged Tmem106b knockout mice display gait deficits in
7 coincidence with Purkinje cell loss and only limited signs of non-motor dysfunction. *Brain*
8 *Pathol*. 2021;31:223-38. doi:10.1111/bpa.12903
- 9 62. Davies NM, Holmes MV, Davey Smith G. Reading Mendelian randomisation studies: a guide,
10 glossary, and checklist for clinicians. *Bmj*. 2018;362:k601. doi:10.1136/bmj.k601
- 11 63. Zhao H, Rasheed H, Nost TH, Cho Y, Liu Y, Bhatta L, et al. Proteome-wide Mendelian
12 randomization in global biobank meta-analysis reveals multi-ancestry drug targets for
13 common diseases. *Cell Genom*. 2022;2:None. doi:10.1016/j.xgen.2022.100195
- 14 64. Hernán MA, Wang W, Leaf DE. Target Trial Emulation: A Framework for Causal Inference
15 From Observational Data. *Jama*. 2022;328:2446-7. doi:10.1001/jama.2022.21383

1 **FIGURE LEGENDS**

2

3 **Figure 1. Overview of the study design.**

4 MR, Mendelian randomization. AD, Alzheimer's disease. pQTL, protein quantitative trait
5 locus. IVW, inverse variance-weighted method. SMR, summary-data-based Mendelian
6 randomization. eQTL, expression quantitative trait locus. sQTL, splicing quantitative trait
7 locus. mQTL, methylation quantitative trait locus. DNA, deoxyribonucleic acid. GTEx,
8 Genotype-Tissue Expression. GoDMC, Genetics of DNA Methylation Consortium. ACE,
9 angiotensin-converting enzyme. ACEI, angiotensin-converting enzyme inhibitor. ARB,
10 angiotensin receptor blocker.

11

12 **Figure 2. Multi-omic validation results in blood and brain for the preliminary top**
13 **findings.**

14 Only eQTL and mQTL MR results are shown here; see detailed sQTL MR results in **Figure**
15 **S12-13.**

16 * With evidence for colocalization (i.e., either colocalized or LD-checked).

17 # Passed the HEIDI test (i.e., $P_{\text{HEIDI}} > 0.05$).

18 pQTL, protein quantitative trait locus. MR, Mendelian randomization. eQTL, expression
19 quantitative trait locus. mQTL, methylation quantitative trait locus. sQTL, splicing
20 quantitative trait locus. LD, linkage disequilibrium. HEIDI, heterogeneity in dependent
21 instruments.

22

23 **Figure 3. Association of angiotensin-converting enzyme inhibitor vs. angiotensin**
24 **receptor blocker with the incidence of Alzheimer's disease in UK Biobank.**

25 Model 1 was adjusted for age at recruitment, sex, and ethnicity.

26 Model 2 was additionally adjusted for hypertension, diabetes, hyperlipidemia,
27 cerebrovascular diseases, traumatic brain injury, and diseases of the nervous system.

28 Model 3 was further adjusted for smoking status, alcohol use, body mass index, income, and
29 educational level.

30 ACEI, angiotensin-converting enzyme inhibitor. ARB, angiotensin receptor blocker. HTN,
31 hypertension. HR, hazard ratio. CI, confidence interval.

32

33 **Figure 4. The use of ACE inhibitors is associated with AD risk as compared with ARBs.**

34 RAAS, renin-angiotensin-aldosterone system; Ang I/II, Angiotensin I/II; ACE, angiotensin-
35 converting enzyme; ARB, angiotensin II receptor blockers; AT receptor, Angiotensin
36 receptor. AD, Alzheimer's disease.

Table 1. Top findings from plasma proteome-wide Mendelian randomization.

Protein	N of SNP	MR Method	OR (95% CI)	Original p-value	Corrected p-value*	Colocalization†	Heterogeneity‡	Pleiotropy§	Reverse causation¶	Bidirectional effect#
Single-cis										
GRN	1	Wald ratio	0.79 (0.74-0.84)	2.19E-12	1.58E-09	Colocalized	-	-	FALSE	FALSE
ACE	1	Wald ratio	0.91 (0.88-0.93)	6.07E-12	4.38E-09	LD-checked	-	-	FALSE	-
CD55	1	Wald ratio	0.90 (0.86-0.93)	1.62E-09	1.17E-06	LD-checked	-	-	FALSE	FALSE
TREM2	1	Wald ratio	0.67 (0.58-0.78)	6.95E-08	5.02E-05	LD-checked	-	-	FALSE	-
TMEM106B	1	Wald ratio	1.16 (1.09-1.23)	1.92E-06	1.38E-03	LD-checked	-	-	FALSE	-
LILRB1	1	Wald ratio	0.95 (0.93-0.97)	4.04E-06	2.92E-03	LD-checked	-	-	FALSE	FALSE
SIRPA	1	Wald ratio	1.03 (1.02-1.05)	1.37E-05	9.88E-03	LD-checked	-	-	FALSE	-
SIGLEC9	1	Wald ratio	1.03 (1.02-1.04)	4.30E-05	3.10E-02	Not colocalized	-	-	FALSE	FALSE
Multiple-cis										
IDUA	3	Generalized IVW	1.06 (1.05-1.08)	6.37E-21	4.60E-18	Colocalized	TRUE	FALSE	FALSE	FALSE
LILRB2	3	Generalized IVW	1.04 (1.02-1.06)	1.37E-06	9.90E-04	Not colocalized	TRUE	FALSE	FALSE	FALSE
TCN2	4	Generalized IVW	0.98 (0.97-0.99)	2.87E-06	2.07E-03	Not colocalized	FALSE	FALSE	FALSE	FALSE
CTSH	3	Generalized IVW	1.05 (1.02-1.07)	2.00E-05	1.44E-02	Not colocalized	FALSE	FALSE	FALSE	FALSE
GPC5	3	Generalized IVW	1.04 (1.02-1.05)	3.24E-05	2.34E-02	Not colocalized	FALSE	FALSE	FALSE	FALSE
cis + trans										
LILRA4	2 (1 cis)	IVW	0.89 (0.85-0.95)	9.05E-05	6.61E-03	Not colocalized	FALSE	-	FALSE	FALSE
IL6ST	4 (1 cis)	IVW	1.09 (1.04-1.14)	1.51E-04	1.10E-02	Not colocalized	FALSE	FALSE	FALSE	FALSE

* Corrected using the Bonferroni method (single-cis: 593 proteins; multiple-cis: 124 proteins; cis + trans: 73 proteins).

† Findings with evidence for colocalization (i.e., posterior probability for a shared causal variant > 80%) shown as “Colocalized”; findings without evidence for colocalization but passing LD-check shown as “LD-checked”; others shown as “Not colocalized”; colocalization analysis not applicable for some findings due to the unavailability of full summary data.

‡ Tested by Cochran’s Q statistics, with p-value < 0.05 defined as having evidence for heterogeneity (shown as “TRUE”); not applicable for some findings due to insufficient numbers of SNPs.

§ Tested by the MR-Egger intercept test, with p-value < 0.05 defined as having evidence for unbalanced horizontal pleiotropy (shown as “TRUE”); not applicable for some findings due to insufficient numbers of SNPs.

¶ Tested by Steiger filtering, with p-value < 0.05 defined as having evidence for reverse causation (shown as “TRUE”).

Tested by bidirectional MR, with IVW p-value < 0.05 for an effect of Alzheimer’s disease on the protein level defined as having evidence for bidirectional effect (shown as “TRUE”); not applicable for some findings due to the unavailability of full summary data.

SNP, single nucleotide polymorphism. MR, Mendelian randomization. OR, odds ratio. CI, confidence interval. IVW, inverse variance weighted method. LD, linkage disequilibrium.

GRN, granulins. ACE, angiotensin-converting enzyme. CD55, complement decay-accelerating factor. TREM2, triggering receptor expressed on myeloid cells 2. TMEM106B, transmembrane protein 106B. LILRB1, leukocyte immunoglobulin-like receptor B1. SIRPA, signal-regulatory protein alpha. SIGLEC9, sialic acid-binding immunoglobulin-like lectin 9. IDUA, alpha-L-iduronidase.

LILRB2, leukocyte immunoglobulin-like receptor B2. TCN2, transcobalamin II. CTSH, cathepsin H. GPC5, glypican 5. LILRA4, leukocyte immunoglobulin-like receptor A4. IL6ST, interleukin 6 signal transducer.

Table 2. Evaluation of the top findings.

Evaluation criteria	single- <i>cis</i> analysis top findings								multi- <i>cis</i> analysis top findings					<i>cis</i> + <i>trans</i> analysis top findings		
	GRN	ACE	CD55	TREM2	TMEM106B	LILRB1	SIRPA	SIGLEC9	IDUA	LILRB2	TCN2	CTSH	GPC5	LILRA4	IL6ST	
Plasma pQTL MR	Bonferroni-corrected $P < 0.05$?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
	(If yes above) Colocalized/LD-checked?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	No	No	No	No	No	
<i>cis</i>-eQTL SMR in blood or brain	Any results with $P < 0.05$?	No	Yes	Yes	N/A	No	No	Yes	Yes	Yes	Yes	No	Yes	N/A	No	No
	(If yes above) HEIDI test $P > 0.05$?	-	Yes	No	-	-	-	No	Yes	Yes	No	-	No	-	-	-
	(If yes above) Effect direction plausible?*	-	Yes	-	-	-	-	-	Yes	Yes	-	-	-	-	-	-
<i>cis</i>-sQTL SMR in blood or brain	Any results with $P < 0.05$?	N/A	Yes	Yes	N/A	Yes	No	Yes	Yes	Yes	Yes	No	Yes	N/A	No	Yes
	(If yes above) HEIDI test $P > 0.05$?	-	Yes	No	-	Yes	-	Yes	Yes	Yes	No	-	No	-	-	No
<i>cis</i>-mQTL SMR in blood or brain	Any results with $P < 0.05$?	No	Yes	No	N/A	N/A	No	N/A	N/A	No	No	N/A	N/A	N/A	No	N/A
	(If yes above) HEIDI test $P > 0.05$?	-	Yes	-	-	-	-	-	-	-	-	-	-	-	-	-
	(If yes above) CpG in promoter area?†	-	Yes§	-	-	-	-	-	-	-	-	-	-	-	-	-
	(If yes above) Effect direction plausible?‡	-	Yes	-	-	-	-	-	-	-	-	-	-	-	-	-

“N/A”: QTL data not available; “-”: analysis not applicable (due to the previous criterion not being met).


* Same effect direction as in pQTL MR results.


† Checked on <https://www.ensembl.org/>.


‡ Opposite effect direction as in pQTL MR results.


§ cg06751221 (from blood mQTL MR), location: 17:63477520-63477569.

pQTL, protein quantitative trait locus. MR, Mendelian randomization. eQTL, expression quantitative trait locus. SMR, summary-data-based Mendelian randomization. mQTL, methylation quantitative trait locus. sQTL, splicing quantitative trait locus. LD, linkage disequilibrium. HEIDI, heterogeneity in dependent instruments. CpG, cytosine-phosphate-guanine.









RAAS

Ang I

ACE2

ACEI

ACE

AD Risk

ARB

AT1R

AT2R

AT receptor

ACE

Ang II

Mas1 receptor